Serina Therapeutics (SER) grants director Stephen Brannan 15,250 options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Serina Therapeutics, Inc. director Stephen K. Brannan received a grant of stock options covering 15,250 shares of common stock. The options have an exercise price of $1.98 per share and expire on June 17, 2036. They vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the June 17, 2026 grant date, subject to his continued service with the company. Following this grant, he holds 15,250 stock options, reflecting a routine compensation-related award rather than an open-market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Brannan Stephen K.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	15,250	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 15,250 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 15,250 options Exercise price: $1.98 per share Expiration date: June 17, 2036 +1 more

4 metrics

Options granted 15,250 options Stock Option (right to buy) grant on June 17, 2026

Exercise price $1.98 per share Conversion/exercise price of stock options

Expiration date June 17, 2036 Option expiration for director’s award

Holdings after grant 15,250 options Total stock options held following this award

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, Annual Meeting, vesting

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Annual Meeting financial

"vest on the earlier of (i) the day before the next Annual Meeting"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

vesting financial

"subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 07:14 PM Accepted by SEC EDGAR 06/22/2026 - 07:13 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brannan Stephen K.

(Last)

(First)

(Middle)

601 GENOME WAY

SUITE 2001

(Street)

HUNTSVILLE

ALABAMA

35806

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$1.98	06/17/2026		A		15,250		⁽¹⁾	06/17/2036	Common Stock	15,250	$0	15,250	D

Explanation of Responses:

1. The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Remarks:

	/s/ Steven Ledger, Attorney in Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the Serina Therapeutics (SER) Form 4 filing report?

The Form 4 shows director Stephen K. Brannan received 15,250 stock options in Serina Therapeutics. These options are a compensation grant, not an open-market trade, and give him the right to buy common shares at a fixed exercise price.

How many stock options did Stephen K. Brannan receive from Serina Therapeutics?

Stephen K. Brannan received 15,250 stock options from Serina Therapeutics. Each option entitles him to purchase one share of common stock, representing a standard equity compensation award for his role as a director of the company.

What is the exercise price of Stephen K. Brannan’s Serina Therapeutics options?

The options have an exercise price of $1.98 per share. This means Brannan can buy Serina Therapeutics common stock at $1.98 per share upon vesting and before expiration, regardless of the market price at that time.

When do Stephen K. Brannan’s Serina Therapeutics options vest?

The options vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the June 17, 2026 grant date. Vesting is conditioned on Brannan’s continued service with Serina Therapeutics through the applicable vesting date.

When do Stephen K. Brannan’s Serina Therapeutics options expire?

The stock options expire on June 17, 2036. After this expiration date, any unexercised options become worthless, so Brannan must exercise vested options before that date if he wishes to acquire the underlying shares.

Is Stephen K. Brannan’s Serina Therapeutics Form 4 a stock purchase or a grant?

This Form 4 reflects a grant of stock options, not a market purchase. The options were awarded at no upfront cost as compensation and allow Brannan to buy shares later at a fixed exercise price of $1.98 per share.